the researchers identified five studies that compared clinical outcomes with JAK inhibitors versus vedolizumab for ulcerative colitis patients. Four studies looked at tofacitinib (Xeljanz ...

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis ... as well as tofacitinib oral treatment ...